Volastra Therapeutics, Inc.

Volastra Therapeutics has a goal to exploit chromosomal instability (CIN) – the process by which cancer cells divide and are able to evade the body’s normal responses – to develop a new category of ca

After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this m

As 2022 draws to a close, an unusually low number of marquee deals have been made in the biopharma sector. But it has been a hectic year nonetheless, with a high volume of deal-making and the lower va

Repare Therapeutics, Inc. got ample upfront cash, significant earnout potential, the chance to opt back in on US commercialization and, according to analysts, strong validation for its DNA damage rep